Estimation of Crystallinity of Nifedipine-Polyvinylpyrrolidone Solid Dispersion by Usage of Terahertz Time-Domain Spectroscopy and of X-Ray Powder Diffractometer

Journal of Pharmaceutical Sciences

Volumn 104, Issue 12, 2015, Pages 4307-4313

  Takeuchi, Issei ^a   Shimakura, Kemmaro ^a   Kuroda, Hideki ^b   Nakajima, Takehisa ^a   Goto, Satoru ^a   Makino, Kimiko ^a  

^a TOKYO UNIVERSITY OF SCIENCE   (Japan)

^b Otsuka Electronics Co Ltd   (Japan)

Author keywords

amorphous; crystallinity; nifedipine; nondestructive analysis; polyvinylpyrrolidone; solid dispersion; spectroscopy; spray drying; terahertz time domain spectroscopy; X ray powder diffractometer

Indexed keywords

NIFEDIPINE; POVIDONE; POWDER;

ARTICLE; CALCULATION; DISPERSION; HUMIDITY; MEASUREMENT; PHYSICAL CHEMISTRY; TERAHERTZ SPECTROSCOPY; X RAY POWDER DIFFRACTION; CHEMISTRY; CRYSTALLIZATION; POWDER; PROCEDURES; REGRESSION ANALYSIS; TEMPERATURE; X RAY; X RAY DIFFRACTION;

CRYSTALLIZATION; HUMIDITY; NIFEDIPINE; POVIDONE; POWDERS; REGRESSION ANALYSIS; TEMPERATURE; TERAHERTZ SPECTROSCOPY; X-RAY DIFFRACTION; X-RAYS;

EID: 84954394842     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.24671     Document Type: Article

References (17)

1. Hancock BC, Zografi G,. 1997. Characteristics and significance of the amorphous state in pharmaceutical systems. J Pharm Sci 86: 1-12.
2. Taylor LS, Zografi G,. 1998. The quantitative analysis of crystallinity using FT-Raman spectroscopy. Pham Res 15: 755-761.
3. Liu H-B, Chen Y, Zhang X-C,. 2007. Characterization of anhydrous and hydrated pharmaceutical materials with THz time-domain spectroscopy. J Pharm Sci 96: 927-934.
4. Liu H-B, Zhang X-C,. 2006. Dehydration kinetics of d -glucose monohydrate studied using THz time-domain spectroscopy. Chem Phys Lett 429: 229-233.
5. Shen YC, Upadhya PC, Linfield EH, Davies AG,. 2003. Temperature-dependent low-frequency vibrational spectra of purine and adenine. Appl Phys Lett 82: 2350-2352.
6. Fitzgerald AJ, Cole BE, Taday PF,. 2005. Nondestructive analysis of tablet coating thicknesses using terahertz pulsed imaging. J Pharm Sci 94: 177-183.
7. Zeitler JA, Shen Y, Baker C, Taday PF, Pepper M, Rades T,. 2007. Analysis of coating structures and interfaces in solid oral dosage forms by three dimensional terahertz pulsed imaging. J Pharm Sci 96: 330-340.
8. Takeuchi I, Shimakura K, Ohtake H, Takayanagi J, Tomoda K, Nakajima T, Terada H, Makino K,. 2014. Nondestructive analysis of structure and components of tablet coated with film by the usage of terahertz time-domain reflection spectroscopy. J Pharm Sci 103: 256-261.
9. Strachan CJ, Rades T, Newnham DA, Gordon KC, Pepper M, Taday PF,. 2004. Using terahertz pulsed spectroscopy to study crystallinity of pharmaceutical materials. Chem Phys Lett 390: 20-24.
10. Taday PF, Bradley IV, Arnone DD, Pepper M,. 2003. Using terahertz pulse spectroscopy to study the crystalline structure of a drug: A case study of the polymorphs of ranitidine hydrochloride. J Pharm Sci 92: 831-838.
11. Takeuchi I, Tomoda K, Nakajima T, Terada H, Kuroda H, Makino K,. 2012. Estimation of crystallinity of trehalose dihydrate microspheres by usage of terahertz time-domain spectroscopy. J Pharm Sci 101: 3465-3472.
12. Hayase N, Itagaki Y, Ogawa S, Akutsu S, Inagaki S, Abiko Y,. 1994. Newly discovered photodegradation products of nifedipine in hospital prescriptions. J Pharm Sci 83: 532-538.
13. Thongnopnua P, Viwatwongsa K,. 1994. Quantitative analysis of nifedipine in plasma by high-performance liquid chromatography. J Pharm Biomed Anal 12: 119-125.
14. Modi A, Tayade P,. 2006. Enhancement of dissolution profile by solid dispersion (kneading) technique. AAPS Pharm Sci Tech 7: E1-E6.
15. Sugimoto I, Kuchiki A, Nakagawa H,. 1981. Stability of nifedipine-polyvinylpyrrolidone coprecipitate. Chem Pharm Bull 29: 1715-1723.
16. Uekama K, Ikegami K, Wang Z, Horiuchi Y, Hirayama F,. 1992. Inhibitory effect of 2-hydroxypropyl-β-cyclodextrin on crystal-growth of nifedipine during storage: Superior dissolution and oral bioavailability compared with polyvinylpyrrolidone K-30. J Pharm Pharmacol 44: 73-78.
17. g without and with polyvinylpyrrolidone. J Pharm Sci 96: 1131-1138.